# US 2017/0363613 A1 · Simultaneous detection of cannibalism and senescence as prognostic marker for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0363613 A1
- Document ID: US20170363613A1
- Status: Published application
- Kind: A1
- Application number: 15/642,273
- Filed: 2017-07-05
- Published: 2017-12-21
- Earliest claimed: 2012-07-06
- Assignees: Institut Gustave Roussy
- Applicants: Institut Gustave-Roussy
- Inventors: JEAN-LUC PERFETTINI; Guido Kroemer; Eric Deutsch
- Web page: https://patentgrep.com/patent/US20170363613A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/575: for cancer
- G01N 33/57595: {involving intracellular compounds}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.

## Claims

### Claim 29

An in vitro method for detecting cannibalism behavior of a cell, comprising a step of measuring in said cell:
expression level of p53,
expression level of a N-terminal isoform of p53 that lacks N-terminal transactivating domain,
expression level or activity of purinergic P2Y2 receptor,
secreted extracellular ATP,
expression level of p53β, or
expression level of p53γ.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the N-terminal isoform of p53 that lacks N-terminal transactivating domain is 440TP53 or Δ133TP53.

### Claim 31 (depends on 29)

The method according to claim 29, further comprising measuring at least one senescence marker.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the senescence marker is p21WAFI, Ki67, p16, Rb, or SA-β-Gal.

### Claim 33 (depends on 29)

The method according to claim 29, wherein measuring expression level comprises measuring mRNA level.

### Claim 34

A method for treating cancer, said method comprising administering to a patient in need thereof a siRNA inhibiting expression of Δ133TP53, a miRNA inhibiting expression of Δ133TP53, or a siRNA inhibiting expression of p53.

### Claim 35 (depends on 34)

The method of claim 34, wherein said siRNA inhibiting expression of Δ133TP53 is SEQ ID NO:19 or SEQ ID NO:20.

### Claim 36 (depends on 34)

The method of claim 34, wherein said siRNA inhibiting the expression of p53 is SEQ ID NO:17 or SEQ ID NO:18.

### Claim 37 (depends on 29)

The method of claim 29, wherein said cell is a melanoma, spitz tumor, prostate cancer, colon carcinoma, liver carcinoma, breast cancer, lung cancer, cervical cancer, or a bone cancer cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein said cell is a Triple Negative Breast Cancer cell.

### Claim 39 (depends on 29)

The method of claim 29, wherein the measuring step is performed on a paraffin-embedded tumor tissue sample comprising the cell.

### Claim at position 12

28. (canceled)
